

PRELIMINARY AMENDMENT

U.S. Appln. No. 09/674,377

A3 joint, angiogenic diseases of the eye (e.g. diabetic retinopathy, retinopathy of prematurity, senile macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, etc.), angiofibroma, benign tumors (e.g. hemangioma, acoustic neuroma, neurofibroma, trachoma, granuloma pyogenicum, etc.), hematopoietic malignancies such as leukemia, solid cancers, cancer metastasis and wound granulation, among others. --.

IN THE CLAIMS:

Please add the following new claims:

-- Claim 19. A polypeptide having an amino acid sequence defined by SEQ ID NO:2.

Claim 20. A pharmaceutical composition containing the polypeptide having an amino acid sequence defined by SEQ ID NO:2 as an active ingredient.

GA Claim 21. A pharmaceutical composition for prophylaxis or therapy of a solid cancer or/and cancer metastasis, which comprises the polypeptide having an amino acid sequence defined by SEQ ID NO:2 as an active ingredient.

Claim 22. A pharmaceutical composition as claimed in Claim 21, wherein cancer of solid cancer or cancer of cancer metastasis is lung cancer or mammary cancer.

Claim 23. A pharmaceutical composition effective for inhibition of tumor growth or metastasis, which comprises the polypeptide having an amino acid sequence defined in SEQ ID NO:2 as an active ingredient.

Claim 24. A pharmaceutical composition as claimed in Claim 23, wherein tumor is lung cancer or mammary cancer.

PRELIMINARY AMENDMENT

U.S. Appln. No. 09/674,377

Claim 25. A pharmaceutical composition for prophylaxis or therapy of diseases arising from vascular hyperplasia or/and diseases caused by an excessive or abnormal stimulation of the endothelial cells, which comprises the polypeptide having an amino acid sequence defined by SEQ ID NO:2 as an active ingredient.

94
Claim 26. A pharmaceutical composition as claimed in Claim 25, wherein said disease is a disease selected from the group consisting of rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic diseases of the eys, angiofibroma, benign tumors, hematopoietic malignancies, wound granulation, enteric adhesion, Crohn's disease, atherosclerosis, scleroderma and overcicatrization.

Claim 27. A pharmaceutical composition for controlling conception, which comprises the polypeptide having an amino acid sequence defined by SEQ ID NO:2 as an active ingredient.

Claim 28. A method for prophylaxis or therapy of a solid cancer and/or cancer metastasis, which comprises administering to a subject a pharmaceutical composition containing the following polypeptide (a) or (b):

- (a) a polypeptide having the amino acid sequence
PyrGlu³²~Val⁴⁷⁸ of heaptocyte growth factor (HGF);
and
- (b) a polypeptide having an amino acid sequence
derived from the amino acid sequence defined in
(a) by the deletion, substitution or addition of
one or more amino acids.

PRELIMINARY AMENDMENT

U.S. Appln. No. 09/674,377

Claim 29. A method for prophylaxis or therapy of a solid cancer and/or cancer metastasis, which comprises administering to a subject a pharmaceutical composition containing the polypeptide having an amino sequence defined by SEQ ID NO:1 or SEQ ID NO:2.

Claim 30. A method for prophylaxis or therapy as claimed in Claim 28 or Claim 29, wherein cancer of solid cancer or cancer of cancer metastasis is lung cancer or mammary cancer.

Claim 31. A method for inhibition of tumor growth or metastasis, which comprises administering to a subject a pharmaceutical composition containing the following polypeptide (a) or (b):

Gay
(a) a polypeptide having the amino acid sequence
PyrGlu³²~Val⁴⁷⁸ of heaptocyte growth factor (HGF);
and

(b) a polypeptide having an amino acid sequence
derived from the amino acid sequence defined in
(a) by the deletion, substitution or addition of
one or more amino acids.

Claim 32. A method for inhibition of tumor growth and metastasis, which comprises administering to a subject a pharmaceutical composition containing the polypeptide having an amino acid sequence defined by SEQ ID NO:1 or SEQ ID NO:2.

Claim 33. A method for prophylaxis or therapy as claimed in Claim 31 or Claim 32, wherein tumor is lung cancer or mammary cancer.

Claim 34. A method for prophylaxis or therapy of diseases arising from vascular hyperplasia and/or diseases caused by an excessive or abnormal stimulation of the endothelial cells,

PRELIMINARY AMENDMENT

U.S. Appln. No. 09/674,377

which comprises administering to a subject a pharmaceutical composition containing the following polypeptide (a) or (b):

- (a) a polypeptide having the amino acid sequence
PyrGlu³²~Val⁴⁷⁸ of heaptocyte growth factor (HGF);
and
- (b) a polypeptide having an amino acid sequence
derived from the amino acid sequence defined in
(a) by the deletion, substitution or addition of
one or more amino acids.

Ch
Claim 35. A method for prophylaxis or therapy of diseases arising from vascular hyperplasia or/and diseases caused by an excessive or abnormal stimulation of the endothelial cells, which comprises administering to a subject a pharmaceutical composition containing the polypeptide having an amino acid sequence defined by SEQ ID NO:1 or SEQ ID NO:2.

Claim 36. A method for prophylaxis or therapy as claimed in Claim 34 or Claim 35, wherein said disease is a disease selected from the group consisting of rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic diseases of the eys, angiofibroma, benign tumors, hematopoietic malignancies, wound granulation, enteric adhesion, Crohn's disease, atherosclerosis, scleroderma and overcicatrization.

Claim 37. A method for controlling conception which comprises administering to a subject a pharmaceutical composition containing the following polypeptide (a) or (b):

- (a) a polypeptide having the amino acid sequence
PyrGlu³²~Val⁴⁷⁸ of heaptocyte growth factor (HGF);
and